Durable Trial Results Might Change The Case For Recursion Pharmaceuticals Stock

Simply Wall St.

Yesterday

Recursion Pharmaceuticals reported new Phase 2 results for REC-4881 in familial adenomatous polyposis, showing broad reductions in upper and lower gastrointestinal polyp burden with a generally well ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2683454726"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2683454726\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2683454726?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","is_english":true,"pubTime":"2026-11-13 10:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2683454726","market":"hk","top_or_hot":-1,"title":"Durable Trial Results Might Change The Case For Recursion Pharmaceuticals Stock","media":"Simply Wall St.","content":"<div>\n<p>Recursion Pharmaceuticals reported new Phase 2 results for REC-4881 in familial adenomatous polyposis, showing broad reductions in upper and lower gastrointestinal polyp burden with a generally well ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rxrx/recursion-pharmaceuticals/news/durable-trial-results-might-change-the-case-for-recursion-ph\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Durable Trial Results Might Change The Case For Recursion Pharmaceuticals Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDurable Trial Results Might Change The Case For Recursion Pharmaceuticals Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-11-13 10:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rxrx/recursion-pharmaceuticals/news/durable-trial-results-might-change-the-case-for-recursion-ph><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Recursion Pharmaceuticals reported new Phase 2 results for REC-4881 in familial adenomatous polyposis, showing broad reductions in upper and lower gastrointestinal polyp burden with a generally well ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rxrx/recursion-pharmaceuticals/news/durable-trial-results-might-change-the-case-for-recursion-ph\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4609","symbol_name":"英伟达持仓股","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rxrx/recursion-pharmaceuticals/news/durable-trial-results-might-change-the-case-for-recursion-ph","article_id":"2683454726","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rxrx/recursion-pharmaceuticals/news/durable-trial-results-might-change-the-case-for-recursion-ph","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2683454726","pubTimestamp":1794536807,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"MMitch LawlerNovember 13, 2026","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4609":"英伟达持仓股","BK4539":"次新股","BK4611":"AI医疗","BK4139":"生物科技","RXRX":"Recursion Pharmaceuticals, Inc.","BK4548":"巴美列捷福持仓"},"translate_title":"持久的试验结果可能会改变 Recursion Pharmaceuticals 股票的情况","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RXRX":1.98},"content_text":"Recursion Pharmaceuticals reported new Phase 2 results for REC-4881 in familial adenomatous polyposis, showing broad reductions in upper and lower gastrointestinal polyp burden with a generally well tolerated safety profile and plans to move toward a registrational trial after ongoing FDA discussions. The durability of polyp burden reductions after REC-4881 treatment and the focus on higher risk larger polyps highlight a potential path for Recursion Pharmaceuticals to translate its AI driven discovery work into a more clinically differentiated asset. This article examines how Recursion Pharmaceuticals' investment narrative may change as REC-4881's durable FAP results further define the clinical pipeline.  Spot other AI-driven healthcare stories that could move next by reviewing the 35 healthcare AI stocks alongside Recursion Pharmaceuticals' REC-4881 update.\nAdvertisementRecursion Pharmaceuticals Investment Narrative Recap To own Recursion Pharmaceuticals, you need to buy into the analyst consensus Narrative on Simply Wall St that an AI native discovery engine can eventually turn today’s pipeline and partnerships into meaningful products while the business is still loss making. The latest quarter showed US$18.6 million in revenue and a net loss of US$119.0 million, so the operating model is still firmly investment heavy. The nearer term catalyst now sits with execution on REC 4881 and other clinical programs, while keeping operating expenses aligned with recent guidance and the extended cash runway. The biggest current risk is that clinical timelines, partnership milestones or future fundraising do not line up cleanly with that cash use, which could prolong heavy losses. The earnings release on November 2, 2026 is the clearest operational lens on that risk reward trade off. Recursion Pharmaceuticals lifted quarterly revenue to US$18.55 million compared with US$5.18 million a year ago, while the quarterly net loss narrowed from US$162.25 million to US$119.04 million and loss per share improved from US$0.36 to US$0.22. Across the first nine months, revenue of US$32.69 million and a loss of US$367.55 million, or US$0.69 per share, underline how dependent the company still is on external funding and partnership receipts. For anyone watching REC 4881’s progress, the key question is whether upcoming data and potential milestones arrive in time to support that burn profile without excessive additional dilution. Recursion Pharmaceuticals' narrative projects US$116.3 million in revenue and US$20.7 million in earnings by 2029. This assumes 28.5% yearly revenue growth and an earnings swing of about US$539.6 million from current earnings of a US$518.9 million loss to the forecast profit. Uncover why Recursion Pharmaceuticals' fair value indicates a 120% potential upside to its current price that could narrow quickly. NasdaqGS:RXRX 1-Year Stock Price Chart Exploring Other Perspectives Some of the most optimistic analysts framed the REC 4881 story very differently to the consensus before this news. You can see that in their assumptions for roughly US$382.1 million of revenue and US$65.7 million of earnings by 2029, compared with the base case of US$116.3 million and US$20.7 million. If you think Recursion Pharmaceuticals’ new FAP data or the appointment of Fred Hassan as Chair could shift how well the pipeline converts into those kinds of numbers, it is worth comparing both narratives and deciding which feels closer to your own expectations. Explore 6 other Recursion Pharmaceuticals fair value estimates, including one that suggests up to 200% upside from the current price. Decide For Yourself Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.  A great starting point for your Recursion Pharmaceuticals research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision. See our latest analysis for Recursion Pharmaceuticals. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Recursion Pharmaceuticals' overall financial health at a glance.  Looking for more investment ideas beyond Recursion Pharmaceuticals? Once you have formed a view on Recursion Pharmaceuticals and REC 4881, it can help to compare that perspective with other opportunities so your portfolio is not leaning on a single story.  If you want potential upside with strict quality filters, scan through 20 high quality undiscovered gems that already show strong fundamentals but still fly under most radars. For readers who care more about resilience than excitement, compare Recursion Pharmaceuticals with 29 resilient stocks with low risk scores that score well on stability and downside protection. If your priority is balance sheet strength to support long development cycles, broaden your watchlist using the list of solid balance sheet and fundamentals (23 results) and see which businesses pair financial flexibility with long term projects.  This article is general in nature and was produced with the assistance of AI automation,\n        based on data and analysis from Simply Wall St. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}